SLRX Salarius Pharmaceuticals

Salarius Pharmaceuticals to Present at BIO Investor Forum Digital

Salarius Pharmaceuticals to Present at BIO Investor Forum Digital
EN
13/10/2020

Underlying

SLRXSalarius Pharmaceuticals

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Salarius Pharmaceuticals

 PRESS RELEASE
Free
SLRX Salarius Pharma...

Salarius Pharmaceuticals Changes Corporate Name to Decoy Therapeutics ...

Salarius Pharmaceuticals Changes Corporate Name to Decoy Therapeutics and Nasdaq Ticker Symbol to DCOY Reflecting Focus on Next-Generation Peptide Conjugate Therapeutics Trading under DCOY to commence on January 8, 2026 Company’s proprietary peptide-conjugate platform leverages AI-enabled computational infrastructure to accelerate candidate selection Capital-efficient 2026 plan features advancing lead antiviral into the clinic while expanding pipeline and partnership opportunities CAMBRIDGE, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) (Salariu...

January 7, 2026 1 EN
 PRESS RELEASE
Free
SLRX Salarius Pharma...

Salarius Pharmaceuticals Announces Adjournment of Annual Meeting, Info...

Salarius Pharmaceuticals Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting HOUSTON, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) (“Salarius” or the “Company”) today announced that its 2025 Annual Meeting of Stockholders (the “Annual Meeting”) scheduled for and convened on December 19, 2025 has been adjourned for the purpose of soliciting additional votes with respect to the proposals described in the Company’s definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission (the “SEC”) o...

December 19, 2025 1 EN
 PRESS RELEASE
Free
SLRX Salarius Pharma...

Salarius Pharmaceuticals Announces Planned Corporate Name and Ticker S...

Salarius Pharmaceuticals Announces Planned Corporate Name and Ticker Symbol Change to Decoy Therapeutics, Reflecting Strategic Pivot to Next-Generation Antiviral and Peptide-Conjugate Platform The combined Company will move forward as Decoy Therapeutics, Inc. and trade on the NASDAQ Stock Market under the ticker “DCOY” effective in early January 2026 Company to focus on advancing lead antiviral programs, expanding platform validation and achieving multiple data milestones Strategic 2026 roadmap designed to accelerate development, expand pipeline breadth, and drive long-term shareholder va...

December 18, 2025 1 EN
 PRESS RELEASE
Free
SLRX Salarius Pharma...

Salarius Pharmaceuticals to Collaborate with Texas Biomedical Research...

Salarius Pharmaceuticals to Collaborate with Texas Biomedical Research Institute on Avian Flu Study Salarius subsidiary Decoy Therapeutics’ influenza fusion inhibitors, designed using its proprietary IMP3ACT™ platform, show excellent in silico free energy binding to the viral target entry protein, supporting potential for anti-flu activity IMP3ACT’s demonstrated capability to create a single antiviral therapeutic against influenza, COVID and RSV has potential to position Salarius to address large existing global commercial opportunity CAMBRIDGE, Mass. and HOUSTON, Dec. 01, 2025 (GLOBE N...

December 1, 2025 1 EN
 PRESS RELEASE
Free
SLRX Salarius Pharma...

Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following ...

Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the Symbol “SLRX” Company has pro forma cash of approximately $14 million following recent public offering HOUSTON and CAMBRIDGE, Mass., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) (Salarius or the Company) cites an error on the S&P CapIQ platform and reiterates that its common stock continues to trade uninterrupted on the Nasdaq Stock Market under the stock ticker “SLRX.” S&P CapI...

November 19, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch